John Clarkson | Chairman
John has a background in molecular biology and significant experience in healthcare and diagnostics businesses. He co-founded Molecular Sensing plc where he was Commercial Director and then Technical Director. Following the successful development of their DNA analysis system, he joined the US-based diagnostics company Osmetech plc when they acquired Molecular Sensing in 2004. John led the formation of Atlas Genetics in 2005 and was founding Chief Executive before becoming Chairman in 2017.
Karen Yates | Finance Director
An Associate of Chartered Management Accountants with over 25 years' experience, Karen has been Finance Director of Atlas Genetics since the Company’s formation. Karen was Finance Director of Horstmann Controls Ltd, before joining Dyson plc as Operations Finance Manager. She then moved to Molecular Sensing plc where she became Finance Director of Molecular Sensors Ltd, later acquired by Osmetech plc.
Ben Arlett | Chief Technology Officer
Ben joined Atlas Genetics as Technical Director in 2008. With a background in mechanical engineering he has spent his career working in innovation and new product development. His experience includes working in products from drug delivery devices to in vitro diagnostics. Ben spent 4 years in the US managing an engineering team in Boston as part of a new venture.
David Whitaker | Operations Director
With a background in mechanical & manufacturing engineering, before joining Atlas in 2013, David was Manufacturing & Mechanical Engineering Manager for DNA Electronics. Prior to this he completed several successful medical device development and transfer to manufacture projects as Principle Consultant for PA Consulting and held manufacturing engineering roles for both Risdon-Pharma and Ivax Pharmaceuticals.
Keith Stauffer | VP Sales & Marketing (US)
Keith has previously worked as VP Marketing for Infectious Diseases at Alere Inc., where most recently he was responsible for developing the pricing strategy, aligning reimbursement initiatives and marketing campaigns for the launch at Alere i™ Flu test, the first CLIA waived POC molecular rapid flu test. Previously, Keith was VP Sales for the Clinical Products Group within Alere, which included infectious disease POC tests. Prior to Alere, Keith worked for Thermo Electron in their Point of Care and Rapid Diagnostics division.